Entities / Company
Karuna Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 11
What's happening
Gone quiet
No new reports in 90+ days-
Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.Well supported3 reports1 development inside
-
Serina Therapeutics' SER-270, a once-weekly injectable therapy, utilizes a proprietary long-acting platform.Some support2 reports
-
The acquisition of Karuna Therapeutics by AbbVie was validated on August 20, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Karuna Therapeutics this week
News at the entities that move Karuna Therapeutics mostConnections
The 2 strongest of 11, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Bristol-Myers Squibb Structural
Bristol-Myers Squibb acquired Karuna Therapeutics, establishing Karuna as a subsidiary.
-
Andrew Miller Transactional
Andrew Miller previously held the leadership role in R&D at Karuna Therapeutics.
History
Events by the month they beganJune 2026
3 events- Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
- Serina Therapeutics' SER-270, a once-weekly injectable therapy, utilizes a proprietary long-acting platform.
- The acquisition of Karuna Therapeutics by AbbVie was validated on August 20, 2025.